Colorectal Cancer
Conditions
Keywords
S-1, Irinotecan, Bevacizumab
Brief summary
The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer
Interventions
S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2). Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15.
Sponsors
Taiho Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy 2. Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) 3. Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment. 4. Age ≥20 years 5. Life expectancy of at least 3 months 6. ECOG PS of 0 or 1 7. Adequate function of major organs as defined below: 1. Hemoglobin ≥9.0g/dL 2. White blood cell count ≥3,500/mm3 3. Neutrophil count ≥1,500/mm3 4. Platelet count ≥100,000/mm3 5. Total bilirubin ≤1.5 mg/dL 6. AST and ALT ≤100 U/L (\<200 U/L in patients with liver metastasis) 7. Serum creatinine ≤1.2 mg/dL 8. Creatinine clearance estimate by the Cockcroft-Gault method \>50 mL/min (reduce initial dosage by one step if ≥50 but \<80 mL/min) 8. Able to take capsules orally. 9. No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator. 10. Voluntary written informed consent.
Exclusion criteria
1. Serious drug hypersensitivity or a history of drug allergy 2. Active double cancer 3. Active infections (e.g., patients with pyrexia of 38℃ or higher) 4. History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year. 5. Uncontrolled hypertension 6. Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes) 7. Moderate or severe ascites or pleural effusion requiring treatment 8. Watery diarrhea 9. Treatment with flucytosine or atazanavir sulfate 10. Metastasis to the CNS 11. Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children. 12. Severe mental disorder 13. Continuous treatment with steroids 14. Urine dipstick for proteinuria should be \<2+ 15. Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism 16. Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks 17. Long-term daily treatment with aspirin (\>325 mg/day) 18. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding 19. Judged ineligible for participation in the study by the investigator for safety reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | any time |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, Response rate, Overall survival, Treatment situation | every course for first three courses, then every other course |
Countries
Japan
Outcome results
None listed